Phaxiam Therapeutics is at the forefront of developing innovative treatments for resistant bacterial infections through the use of phage therapy. This approach utilizes bacteriophages, which are viruses that specifically target and eradicate bacteria, including those that are multi-resistant to antibiotics. Phages are harmless to human cells and offer a highly targeted method of treatment, adapting quickly to bacterial mutations while preserving the microbiota. This specificity and adaptability make phage therapy a promising alternative in the fight against antimicrobial resistance (AMR), a significant global health challenge responsible for over a million deaths annually.

The company has made significant strides in validating its phage therapy solutions, including the development of the phagogram, the first CE-marked Phage Susceptibility Test (PST). This test demonstrated a remarkable 98% response rate against 105 clinical strains of Staphylococcus aureus, showcasing the efficacy of Phaxiam's phage products. With a mission to become a leader in phage therapy, Phaxiam is actively addressing the urgent medical need posed by AMR, as evidenced by its recent FDA clearance to initiate Phase II clinical studies targeting prosthetic joint infections caused by Staphylococcus aureus.

France

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Infectious Diseases

Phaxiam Therapeutics

Prosthetic joint infection

Staph aureus

PHAXIAM phages

Endocarditis infections

Cancer

Pancreatic cancer

<p class="font_7">ERYTECH’s lead product candidate eryaspase, L-asparaginase encapsulated inside a donor-derived red blood cell, is a novel product candidate aimed at targeting cancer cells’ altered amino acid metabolism. L-asparaginase is well-established in the treatment of acute lymphoblastic leukemia, but toxicity has prevented its use in the most fragile patients and in other indications. By encapsulating the L-asparaginase into red blood cells, eryaspase aims to enlarge its therapeutic window, and broaden the scope to other oncology indications such as pancreatic cancer and triple-negative breast cancer.</p>

Phaxiam Therapeutics

Company Details